Search
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigational[A252270] The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. … However, its use for the treatment of acute ischemic stroke (AIS) has increased over the years.
Products: ACTILYSE 10 MG FLAKON, 1 ADET, ACTILYSE 50 MG FLAKON, 1 ADETDiatrizoate
go.drugbank.com/drugs/DB00271ApprovedVet approvedAs diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
Mixtures: UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 100 ML, UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 50 MLSynonyms: 3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acidEvolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalPCSK9 is a protein that targets LDL receptors for degradation, therefore reducing the liver's ability to remove LDL-cholesterol (LDL-C), or "bad" cholesterol, from the blood. … It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies.
Products: REPATHA® 140 MG/ML, REPATHA 140 MG/ML SC ENJEKSIYONLUK COZELTI ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADETTestosterone undecanoate
go.drugbank.com/drugs/DB13946ApprovedInvestigationalTestosterone undecanoate is the ester prodrug of [testosterone] and has a mid-chain fatty acid at the carbon 17β position. … [L35970] It was developed via fatty acid esterification of testosterone in order to achieve orally administer testosterone.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesProducts: Nebido 1000 mg/4 ml Injektionslösung, Testomed 1000 mg/4 ml InjektionslösungAtazanavir
go.drugbank.com/drugs/DB01072ApprovedInvestigationalAtazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. … Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsProducts: ATAZANAVIR ( AS SULFATE ) CAPSULES 150 MG, ATAZANAVIR (AS SULFATE) CAPSULES 300 MG.Indapamide
go.drugbank.com/drugs/DB00808ApprovedInvestigational[A204155] Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. … [A204134] When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index
Mixtures: Triplixam 10 mg/2,5 mg/10 mg Filmtabletten, COVERATRIX® 10 MG. / 2.5 MG. / 10 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTrospium
go.drugbank.com/drugs/DB00209ApprovedInvestigational._ and was granted FDA approval in 2007.[L6211]
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: SPASMEX 30 MG FILM TABLET, 100 ADET, SPASMEX 30 MG FILM TABLET, 50 ADETDeferoxamine
go.drugbank.com/drugs/DB00746ApprovedInvestigationalIt forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Products: DESFERAL 500 MG IM/IV/SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON, 10 ADET, Desferal 500 mg - TrockenstechampullenMoclobemide
go.drugbank.com/drugs/DB01171ApprovedInvestigationalDue to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri- or heterocyclic antidepressants [A31901]. … Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesProducts: ZOPRAX TABLETAS 100 MG, MOCLOBEMID-NEURAX 150 MGAlirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalFrom this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. … Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of
Products: PRALUENT 150 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN), PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 150 MG/ML